Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690833 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis
A Phase 4 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT00690833: Completed Phase 4 study, sponsored by Wake Forest University.
NCT00690833 is a Phase 4 study that has completed, run by Wake Forest University. The registered enrollment target is 41 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00690833, a Phase 4 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
Primary Outcome
The Investigator global assessment at Week 4 is based on an overall scale of 0-4 with 0 being clear and 4 being very severe
Interventions
- DRUG topical desonide hydrogel 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
What the finished NCT00690833 record still lists
NCT00690833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which topical desonide hydrogel 0.05% is the first listed.
NCT00690833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00690833 about?
NCT00690833 is a clinical study titled "Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis". The purpose of this research study is to better understand how this study drug works when people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug Administration (FDA) for atopic dermatitis.
What is the current status of trial NCT00690833?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2007-08. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00690833?
The interventions under investigation include: topical desonide hydrogel 0.05% (DRUG).
Who is sponsoring clinical trial NCT00690833?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00690833's enrollment target sits among peer trials
41 1390th of 2000 higher than 604 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia